Tanya Siddiqi

May 25, 2024 | curetoday.com | Tanya Siddiqi

The patient was starting his retirement, on the verge of enjoying well-earned travel and time together with his wife. No one expected a cancer diagnosis to halt his plans, but it did, and he and his spouse were overwhelmed and deeply distressed. It took the understanding and compassion of Kelly Davey, NP, to see the couple through their ordeal, which, despite multiple attempts at treatment, did not end as hoped.

Dec 10, 2023 | brnw.ch | Michael Wang |Tanya Siddiqi |Leo Gordon |Matthew A Lunning

Your PrivacyASCO is committed to transparency regarding our websites and the ways we process data. When you visit our site, we may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences, your location, or your device and is mostly used to make the site work as you expect it to and to personalize your web experience with us. Because we respect your right to privacy, you can choose not to allow some or all types of cookies.

Dec 10, 2023 | ascopubs.org | Michael Wang |Tanya Siddiqi |Leo Gordon |Manali K. Kamdar

Patients with relapsed/refractory MCL after ≥2 lines of prior therapy, including Bruton tyrosine kinase inhibitor (BTKi), alkylating agent, and CD20-targeted agent, received lisocabtagene maraleucel (liso-cel) at a target dose level of 50×10 6 (DL1) or 100×10 6 (DL2) CAR + T cells. Primary endpoints were adverse events, dose-limiting toxicities, and objective response rate (ORR) by independent review committee per Lugano criteria. Of 104 leukapheresed patients, liso-cel was infused into 88.

Dec 10, 2023 | ascopubs.org | Michael Wang |Tanya Siddiqi |Leo Gordon |Manali K. Kamdar

Liso-cel demonstrated high CR rate and deep, durable responses with low incidence of grade ≥3 CRS, NE, and infections in patients with heavily pretreated R/R MCL, including those with high-risk, aggressive disease. Of 104 leukapheresed patients, liso-cel was infused into 88.

Jun 6, 2023 | thelancet.com | Tanya Siddiqi |David Maloney |Saad S. Kenderian

Background Patients with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma for whom treatment has failed with both Bruton tyrosine kinase (BTK) inhibitor and venetoclax have few treatment options and poor outcomes. We aimed to evaluate the efficacy and safety of lisocabtagene maraleucel (liso-cel) at the recommended phase 2 dose in patients with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma.